The Informed Consent Process in Health Research with Under-served Populations: A Realist Review Protocol.

Eleanor Hoverd (✉ eleanor.hoverd@nihr.ac.uk)  
University of Warwick  https://orcid.org/0000-0002-8482-655X

Sophie Staniszewska  
University of Warwick

Jeremy Dale  
University of Warwick

Protocol

Keywords: Informed consent, under-served, health research, realist review

DOI: https://doi.org/10.21203/rs.3.rs-72276/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background

The informed consent process aims to provide potential participants with information about health research that enables them to make an informed decision as to whether they choose to participate, or not. However, it remains unclear as to whether the process is effective for those whom are under-served in health research. It is a pivotal issue within health research that the diversity of people who participate is broadened. The National Institute for Health Research (NIHR) pledges to support equality, diversity and inclusion, actively creating opportunities for all citizens whom are eligible, to take part in health research.

Methods

In order to understand how the informed consent process for under-served populations in health research works, under what circumstances and in what respects, a realist review approach will be undertaken. Searches will be carried out using electronic databases (EMBASE, MEDLINE, Web of Science and PsychInfo), along with selected websites and grey literature. Development of initial rough programme theory (ies) will lead to a more refined programme theory that will provide an explanation of context, mechanism and outcomes. Stakeholder involvement by NIHR (Public) Research Champions, health professionals and clinical academics will provide expert opinion about concepts and programme theory.

Discussion

Findings of this realist review will highlight how the informed consent process in health research affects the experience and decision-making process of potential participants from under-served populations. They will be written up in accordance with RAMESES guidelines and disseminated to patients and the public, health researchers, health professionals and policymakers through peer-reviewed publication, presentations and discussions. The review will contribute to our understanding of the mechanisms that trigger both positive and negative outcomes in the informed consent process for those whom are often under-represented in health research to inform policy, study design and delivery.

Background

Health research in the twenty-first century must be inclusive in order to generate evidence that is applicable to diverse populations [1]. However, it is recognised that many groups are under-served in health research. There is an increasingly urgent need to address this. One factor contributing to this is the informed consent process. Through a lack of flexibility and sensitivity in the way in which it is designed and delivered, [2–4] participants from under-served populations may be inadvertently excluded [5–7].

Defining underserved as a concept is vital to developing understanding of how informed consent enables or inhibits diversity in research. The INCLUDE (Innovations in Clinical Trials Designs in Under-represented groups) project has been looking to improve representation of under-served groups in clinical trials in the UK [8]. Following involvement from a range of stakeholder groups as part of the project, it is recommended that the term under-served is preferred when describing the many groups of people whom are often not represented in health research, such as minority ethnic groups [8]. It is unclear from the wider literature as to what a suitable definition of under-served groups is, as this varies according to setting and perspective, but they are often those groups whom are met with difficulties in accessing and utilising resources [9]. It is a frequently used term used by the World Health Organisation (WHO) often describing areas as rural, remote, or poor and populations as excluded or vulnerable, although a definition is not evident [10, 11]. This
will be explored further during the realist review as part of mapping out the territory, identifying the types of populations that are under-served in health research, as part of the scoping the literature [12]. In addition, a suitable working definition will be proposed by the stakeholder groups for the purpose of this review.

Previous studies on the informed consent process have reported that potential participants lack of understanding of study information is a significant issue [13–15]. The informed consent process, when carried out effectively, respects the decision made by a potential participant as to whether they wish to take part, or not, in health research [16]. However, evidence suggests that information provided to potential participants is often complicated and lengthy causing concern around issues of comprehension and effectiveness, putting into question the validity of the whole process [3, 16–19]. This raises questions about the effectiveness and appropriateness of the informed consent process - the way in which it is designed and delivered for populations that may not be suited to receiving a universal process and about the circumstances under which it works, if it works [4, 5].

Previous systematic reviews have focussed on understanding and improving the informed consent process, although little has changed in the way in which it is carried out [13, 18, 20]. There is some evidence to suggest that the use of multi-media interventions to improve understanding, along with extended discussions during the informed consent process may be effective, although these interventions have not been adopted in practice [18, 21]. In the past, there have been a number of concerns from researchers and Institutional Review Boards (IRBs) including how to conduct appraisal of computer-based informed consent, costs associated with the development of new technology to support the informed consent process, lack of support from government agencies and issues around protecting confidentiality, thus resulting in reluctance to change from traditional consent methods [15, 26].

Since these systematic reviews were carried out, global healthcare has rapidly begun to adopt digital technology to deliver interventions, provide information and communicate to patients [22]. The World Health Organisation (WHO) has recently produced a Global Digital Health Strategy 2020–2024, aiming to make health systems around the world stronger, for the benefit of all populations [23]. The need for further research to understand how the informed consent process is experienced and understood by those whom are under-served is vital in order to contribute to the development of a more flexible, innovative informed consent process. This may also provide further benefit in understanding the requirements of these populations in order to develop a digital process that has the capability of being utilised more broadly within health care [18].

Failing to include diverse representation of populations in health research risks producing findings that are not applicable, nor meaningful to the wider population and can lead to methodological weakness [24]. It can also limit discovery and produce unforeseen consequences, preventing the broader population from benefitting [25]. The recent effect of COVID-19 on black, Asian and minority ethnic (BAME) populations demonstrates the urgent need for ensuring health research is inclusive [26], providing an opportunity to identify how research processes are supporting this requirement. There is a need for further evidence to help policymakers and health researchers: improve the process to make health research more inclusive; to keep up with the diverse needs of our population; improve our understanding of what works and for which groups; adapt it to work in various settings and under different conditions, whilst maintaining its validity.

**Realist Review Methodology**

The informed consent process is complex [13,17,18, 27]. A realist review will advance knowledge by offering a deeper understanding as to how, why and in what contexts, works best for enabling under-served populations to make an informed decision as to whether to participate in health research [28]. Whilst there is considerable literature on the
informed consent process in health research, there remains a gap in addressing the complexities of the process that affect the opportunity for under-served individuals to make a decision about taking part.

This realist review will integrate the viewpoints of NIHR (Public) Research Champions and health professionals, at second and third iterations, through refining the programme theory. They will be asked to offer their views as ‘content’ experts concerning the believability and comprehensiveness of a programme theory and offer suggestions of locating further data [29]. Stakeholders will provide expert opinion that cannot be obtained in the literature, adding value to the review [28]. This iterative process will add to the evidence in a way that a traditional systematic review cannot [30]. The experiences of these groups will help to clarify how the informed consent process is expected to work, whilst including and referring to the evidence in order to explain the mechanisms.

Realist reviews seek to develop theories using an explanatory approach which is particularly important for understanding informed consent as it is a complex social intervention, that heavily depends on the context of delivery and how it is delivered [31]. In this instance, the CMO formation (C-context, M-mechanism, O-outcomes) will be used to explore the experience and understanding of receiving information during the informed consent process with under-represented populations (O), building the principal mechanisms (M) and its connecting contexts (C) [32]. This will lead to the development of a programme theory that will be tested and refined, providing an explanation as to how the informed consent process operates [12].

An important aspect of the realist review is its ability to provide a fluid framework that facilitates consideration of how a process such as informed consent is controlled and understood by government authorities; in the UK, these include the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA), IRBs, researchers, health professionals and participants in health research - it is dependent upon multiple mechanisms - which have the potential to fail, or be ineffective [31]. This realist review will focus on providing evidence around what the current informed process experience looks like for under-served populations and in addition, will explore which mechanisms, contexts and conditions affect their decision-making during the informed consent process.

This realist review protocol has been written according to the PRISMA-P guidelines [33].

Methods

Review aim, questions and objectives

Aim

The aim of this review is to answer the over-arching question: What are the experiences of under-served populations with the informed consent process and its impact on decision-making about whether or not to participate in health research?

Objective

To develop and refine a programme theory identifying the contexts and mechanisms that affect communication of information and experience during the informed consent process, for under-served populations.

A further sub-set of questions identify the more specific aims to answer this question.

Research questions
1. What contextual factors influence the decision to take part in health research in under-served populations?
2. How do under-served participants experience the information provided during the informed consent process in health research?

**Stakeholder groups**

This review will involve stakeholders (described below) who will be invited to comment on the process of informed consent in health research as NIHR (Public) Research Champions, health professionals and clinical academics. NIHR (Public) Research Champions are volunteers whom are interested in raising awareness about health research, particularly to those whom often do not participate [34]. This mix of stakeholders are considered to hold positions that are relevant to the topic of the review and to have a vested interest on behalf of under-served populations [35]. Ethical approval is not required as stakeholders will be contributing collaboratively to content and dissemination, not providing data [36-38]. These stakeholders will provide advice on what may be in a programme theory, helping with refinement and sharing views on the credibility of a programme theory, along with suggestions as to where to find more data [29]. They will be considered “content” experts as entitled by Wong (2018) and will be invited to be involved and asked to provide input at certain steps in the review as displayed in table 1 [29]. It will be beneficial to share the findings with health researchers and policymakers such as the National Institute for Health Research (NIHR) and Health Research Authority (HRA), but it is not possible for the scope of this review to involve them in discussions as this would require more time and resources to do so.

**Table 1**

| Stakeholder input |
|-------------------|
| Through purposive sampling, invitation via email will be to the following potential stakeholders to join a realist review discussion group via Microsoft Teams (or other) video-conferencing: |
| - Staff from the Clinical Research Network (CRN) West Midlands that have experience of working within a health research setting |
| - Clinical academics from the Clinical Trials Unit, Warwick Medical School |
| - Health professionals in the West Midlands from a secondary care setting that have experience of delivering health research |
| - NIHR (Public) Research Champions who are part of the Clinical Research Network West Midlands Equality, Diversity and Inclusion working group |
| There will be two separate groups, one each for professionals and NIHR (Public) Research Champions, whom will meet virtually, up to three times during the following points: |
| - at the second iteration: meeting to develop a working definition for the term under-served and to prioritise programme theory (ies) |
| - at the third iteration: meeting to refine programme theory |
| - end of project final meeting when review is complete |

Due to the current social distancing requirements associated with the COVID-19 pandemic discussions with stakeholders will be held using the Microsoft Teams online platform unless stakeholders indicate a preference for other technology that would support accessibility. Stakeholders will be sent an invitation to join the meeting via EH, to limit accessibility to those invited. There will be two, separate stakeholder group meetings, one for health
professionals/clinical academics and one for NIHR (Public) Research Champions, that will enable uninhibited discussions [35]. A maximum of 10 participants per meeting will be set to provide the opportunity for all to speak. Stakeholders will be contacted via email before the scheduled meetings to offer a brief training session on Microsoft Teams (if required) and a summary of what to expect to ensure meetings run smoothly.

**Patient and Public Involvement**

The initial ideas for this review were discussed with NIHR (Public) Research Champions at a local, West Midlands primary care Patient Public Involvement (PPI) meeting held by EH. It was agreed that the topic is important and relevant to patients and the public. NIHR public Research Champions are volunteers who raise awareness about health research, in particular with those whom are less likely to participate [39]. NIHR (Public) Research Champions will form a key stakeholder group and will be central to providing expertise at the second and third iterations of the review. At the end of the review, they will comment on the findings and contribute to the dissemination plan through helping to write a lay summary and designing a leaflet for dissemination to their peers.

Patient and Public Involvement through NIHR (Public) Research Champions will provide insights and opinion on the informed consent process including what it should look like in health research, along with sharing valuable input throughout the realist review steps [38]. PPI will be facilitated through inviting an existing Equality, Diversity and Inclusion working group from the Clinical Research Network West Midlands that consists of NIHR (Public) Research Champions whom are interested in tackling health inequalities within health research specifically. In addition to the NIHR (Public) Research Champions, snowballing of interest from other PPI volunteers whom express interest in providing expertise will be invited at their request, to comment at planned meetings also.

**Multi-disciplinary involvement**

In addition to the PPI stakeholder group, a multi-disciplinary group of health care professionals, clinical academics and the PPI Lead of the CRN West Midlands Equality, Diversity and Inclusion working group from the West Midlands will be invited for consultation, drawing on their expertise and insider knowledge related to the informed consent process in health research and under-served populations. The group collectively will have a variety of experiences including: carrying out the informed consent process with local populations from all across the West Midlands, including rural and urban areas and in various settings, such as care homes, secondary care settings and general practice; experience of recruiting participants from under-served populations; a vested “stake” in reducing health inequalities in health research and also insight into the difficulties of recruiting potential participants from under-served populations in health research. This experience and knowledge will be beneficial when prioritising, refining programme theory and building CMOC’s (Context, Mechanism, Outcomes Configurations) [29]. Some professionals may have experience of not being able to carry out the informed consent process with particular patients, or in certain locations and these experiences are also considered vital in helping to provide explanations of what works and what doesn’t, for whom and in what context.

As recommended by Pawson et al (2005), a series of steps in accordance with standard Cochrane headings can provide a helpful approach to carrying out a realist review. Therefore, this review will be conducted in this logical way [31].

**Step 1. Scoping search and identification of a programme theory**
It is recognised that it is natural for a scoping search to be an iterative process and often challenging, due to the complexity of the intervention under study [40]. This may require refining of the research question(s) for a length of time during the review [41]. EH will carry out the scoping search based on terms focussed on the intervention (informed consent). This will enable identification of existing theories about how under-served populations experience and understand information provided during the informed consent process in health research and in what context, and under what conditions it is effective, or ineffective. A combination of electronic databases, along with websites such as the Health Research Authority (HRA) will be searched, see table 2. It is also acknowledged that through discussions with stakeholders, further sources may be identified and used to inform the programme theory. The support of an Information Specialist to support searching will also be requested, as recommended by Pawson (2006) [32].

### Table 2

| Type of Source | Name of source (s) |
|---------------|--------------------|
| Electronic Databases | EMBASE, MEDLINE, Web of Science, PsychINFO |
| Websites | UCL IRIS (Institutional Research Information Service), HRA, MHRA, NIHR, (formerly INVOLVE), legislation.gov.uk |
| Grey literature | Search engines (Google), Editorials, Opinion pieces |
| Stakeholders | e.g. reports, conference presentations |

A list of important intervention theories for exploration will be compiled that will be of relevance to the research questions. Following the creation of a list of all relevant programme theories, they will be shortlisted according to which are deemed to be the most important for further exploration [31].

### Step 2 Evidence searching

Purposive sampling will be used to search the literature. Using this sampling method will enable an iterative process that will allow repeated searching and refinement of search terms as understanding develops throughout the review [31]. Pawson et al (2005) suggest approaching the search in four parts as follows:

1. Carry out a background search of the literature
2. Develop, refine, verify, or disprove a theory based on available evidence
3. Implement the search strategy to identify relevant evidence
4. Perform a final search that will help to identify further studies that may contribute to sharpening the programme theories discovered.

Free text and MeSH (medical subject headings) will be used to ensure thoroughness. Each database will require an individual search which will be fine-tuned accordingly, to ensure relevant papers are identified. The reference lists of papers included will be examined for locating further papers that may add to the richness of data. To ensure validity and diligence of the search process experts within the field of interest will be contacted to verify results. Following each stage of the search, it will be essential to check whether any new literature adds anything different to the knowledge around the intervention (informed consent process). This will help to determine when saturation has been reached [31].

Searching will be conducted and reported in accordance to RAMESES standards [38]. An example of an initial search strategy for MEDLINE, containing the search terms, is available in Additional file 1 (Search 1).
Step 3 Critical appraisal and data extraction

Preliminary screening of the literature using article titles and abstracts will identify all papers that are potentially relevant. Secondary screening of full-texts by the main reviewer (EH) will be carried out according to pre-determined inclusion/exclusion criteria (see table 3). A second reviewer will screen a 10% sample of the results, for agreement, with a record of exclusions made throughout the screening process. Any disagreements will be settled by the stakeholder group. Records will be managed using Endnote Online to manage references.

Table 3

| Inclusion/Exclusion criteria |
|-----------------------------|
| **Inclusion criteria**      |
| - Quantitative and qualitative studies, grey literature, websites, stakeholder recommendations (e.g. reports, conference papers). |
| - The search will be limited to a 15-year publication period (2005 – 2020) |
| - All studies that report on experiences and decision-making involved in the informed consent process in under-served populations will be included. |
| - Any source of data that is deemed relevant by the stakeholder group. |
| - Literature that explores the concept and practice of informed consent. |
| **Exclusion criteria**      |
| - Studies, or sources of data that are not relevant to the informed consent process in health research in relation to under-represented populations. |

According to Wong (2018) realist reviews must take a logical approach in considering the trustworthiness of data [29]. It is important to note that because this review is developing theory and data will come from many sources, Wong (2018) suggests assessing the trustworthiness of data by [29]:

- Presuming that empirical data has been acquired methodically.
- Deciding if there is lack of clarity around data collection methods, in which case trustworthiness should be regarded with uncertainty.
- Making the effort to locate multiple, pertinent sources of data in relation to facets of programme theory. Relevance is key [29].

In addition to this, utilising a data extraction form will help to provide a reliable approach to data extraction [41]. The data extraction form will be developed once a theoretical framework has been established as this will inform the questions that will need to be asked, to determine if the evidence from the theory areas should be included in the
evidence synthesis. The data extraction form will be piloted on two articles before implementation, but an open-minded approach will be taken as it is understood that it may be necessary to have several forms to avoid a one-size-fits-all approach to extraction [28].

Data extraction forms will be used in conjunction with Pawson et al’s (2005) recommended approach to gathering information through note-taking and annotation [31, 43-45]. Utilising these methods will provide a comprehensive and auditable trail for data extraction and critical appraisal.

**Step 4. Organisation of the evidence**

Synthesis of the evidence will aim to develop, test and refine the programme theory through analysis of the data [46]. Data will be mapped to create a data matrix according to CMOC’s which will help with interpretations and in producing theory [38]. Data synthesis will be guided by the approach used by Rivas et al (2019) to support interpretation and development of the programme theory. Following a similar approach will improve methodological quality through [43]:

- Comparing evidence to gain better understanding
- Amalgamating data that provide evidence of corresponding mechanisms and outcomes
- Further reflecting on evidence that demonstrates opposing outcomes, but similar contexts
- Considering the circumstances of evidence that finds different contexts and outcomes
- Using judgement to determine methodological strengths and weaknesses [30, 47].

**Step 5 Refinement and validation of the programme theory**

The result of the realist review will provide government agencies, IRBs, researchers and health professionals with an explanation of what is effective, what is ineffective and what is unknown about the informed consent process for improving experience and understanding to aid decision-making in under-served populations. These recommendations and findings will include input from the identified key stakeholders and will form what the programme theory is. They may also contribute to further recommendations for developing training on how best to deliver the informed consent process and highlight potential avenues for exploring the design of health research studies.

**Ethics and Dissemination**

Ethical approval is not necessary for this study although all stakeholders will be fully informed of the study intentions. However, there are several ethical considerations to make around patient and public involvement as recommended by Pandya-Wood et al (2017) [19]. Some of these ethical considerations will also be applied to the professional stakeholder group as to ensure a professional approach is taken. These include: role of the public contributor; avoidance of tokenism; the opportunity to withdraw; fairness of opportunity; taking a sensitive approach; respecting confidentiality and valuing public contributions [19] (see table 4).
Role of public contributors  The role of the public contributors will be made clear when they are invited to be part in the stakeholder group, through written information with the opportunity to discuss verbally if they wish. Their contributions will include developing a working definition of the term under-served, involvement in refining programme theory providing their ideas as to what is important when considering and refining programme theory, with sufficient time allocated to allow for discussion and flow of ideas.

Avoidance of tokenism  Details of PPI contributions and how they will be utilised and shaped programme theory will be described in the review.

Opportunity to withdraw  It will be clearly communicated to public contributors that they may withdraw their involvement at any stage in the review process without needing to provide a reason.

Fairness of opportunity  The researcher will seek to engage pragmatically, with an already formed group that represents equality, diversity and inclusion. This will also be a limitation, because the scope of this review will not allow more time, or funds to engage with a larger group.

Sensitive approach  A sensitive approach will be taken with the public contributors with every effort to ensure personal information is not revealed in relation to individuals that are involved, whilst being aware of any potentially, undesirable reactions of members of the group.

Confidentiality  It will be clearly stated to public contributors that should any personal issues be discussed during the meetings, that this information will remain confidential.

Valuing public contributions  A pragmatic approach will be taken with a view to being flexible with technology, utilising what works best. Regular communication to all public contributors will be carried out with their involvement described within the review and how it was included.

The expertise from NIHR (Public) Research Champions, or public contributors, during stakeholder meetings will help to identify the concepts that will build CMOC's, through making judgements about text, whilst utilising the data to confirm, refute, or refine aspects of the programme theory Wong (2018 )[29].

Dissemination

Findings from the review will be disseminated to patients and the public (in the form of a lay summary), researchers, health professionals and policymakers in relation to the informed consent process with under-served populations. The findings will offer deeper understanding about the relationships between the informed consent process and the contexts and mechanisms which influence decision-making by under-served populations. Findings will be shared as set out in table 5. The aim of disseminating findings with policymakers is to influence their thinking [28].
Table 5
Dissemination plan

| Patients and the public                                      | Researchers/Health Professionals                                      | Policymakers                                      |
|-------------------------------------------------------------|------------------------------------------------------------------------|--------------------------------------------------|
| Centre for Engagement and Dissemination (CEDA) (lay summary) | Publication in a peer reviewed journal                                 | Summary of findings emailed to HRA Head of Policy |
| Public Involvement and Lay Accountability in Research and innovation PILAR) (lay summary) | Summarised within NIHR Patient and Public Involvement and Engagement Google Community (link to lay summary) | Summary via NIHR Signals and Connect newsletters |
| West Midlands Research Champion Forum (presentation)         | Poster at academic conference                                          | Email MHRA Director of Inspection, Enforcement and Standards with summary |
| NIHR Patient and Public Involvement and Engagement (PPIE) Google Community (link to lay summary) | Poster Presentation at West Midlands R&D Forum                          | Email MHRA Director of Inspection, Enforcement and Standards with summary |
| Twitter (lay summary)                                       | Twitter/ Warwick Medical School Unit of Academic Primary Care webpage (summary of findings) | Twitter (@HRA News, @MHRApress) - link to findings |

Discussion

The UK is currently lacking policy that drives inclusion in health research. This realist review will derive from the available literature, along with the expertise of stakeholders, a refined programme theory to explain the context, mechanism and outcomes for the informed consent process in health research with under-served populations.

To our knowledge, this is the first realist review aimed at developing an original programme theory on the informed consent process in health research for under-served populations. As with any research there are strengths and limitations. These include:

- using realist methods to explore the contexts and mechanisms of the complexities behind the informed consent process in health research, for under-served populations.

- the involvement of National Institute for Health Research (NIHR) public Research Champions, healthcare professionals and clinical academics in refining the programme theory will ensure the study is relevant.

- availability of evidence relating to under-served populations participating in health research may limit theory building.

- owing to the current COVID-19 pandemic, stakeholder involvement in the programme theory development may be restricted, and will be limited to remote communication.

The results of the review will be useful for policymakers, health researchers and government agencies - sharing explanations about the informed consent process - for creating a health research environment that is more inclusive.

It is worth noting that the current COVID-19 pandemic may potentially cause disruption to this review. This is most likely to affect stakeholder involvement. A flexible approach to stakeholder meetings aims to minimise this as much as possible. Any impact, or variations to the original protocol because of the pandemic will be discussed in the review results paper.

Abbreviations

BAME black, Asian and Minority Ethnic
CEDA  Centre for Engagement and Dissemination
CMO  Context Mechanism Outcome
CMOCs  Context Mechanism Outcome Configurations
CRN  Clinical Research Network
HRA  Health Research Authority
INCLUDE  Innovations in Clinical Trials Designs in Under-represented groups
IRBs  Institutional Review Boards
MHRA  Medicines and Healthcare products Regulatory Agency
NIHR  National Institute for Health Research
PPI  Patient and Public Involvement
PPIE  Patient and Public Involvement and Engagement
WHO  World Health Organisation

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Availability of data and materials
Not applicable.

Competing interests
None declared.

Funding
Eleanor Hoverd is funded by a National Institute for Health Research (NIHR), HEE/NIHR ICA Programme Pre-doctoral Clinical Academic Fellowships grant number NIHR 300317. Funding for the open access charges for the publication of this protocol was provided by the NIHR Clinical Research Network West Midlands.
Authors’ contributions

EH is responsible for the design and drafting of the protocol manuscript. SS and JD critically reviewed and edited the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Authors’ information

Research Nurse/NIHR HEE ICA predoctoral clinical academic fellow, NIHR CRN West Midlands primary care/Unit of Academic Primary Care, Warwick Medical School, University of Warwick, Coventry CV4 7AL. Professor of Patient and Public Involvement (PPI) and Patient Experience, Warwick Research in Nursing, Warwick Medical School, University of Warwick, Coventry CV4 7AL. Professor of Primary Care, Unit of Academic Primary Care, Warwick Medical School. Warwick University, Coventry CV4 7AL.

References

1. Corbett J, D’Angelo C, Gangitano L, et al. Future of Health: Findings from a survey of stakeholders on the future of health and healthcare in England. The Department of Health. 2017. http://www.rand.org/pubs/research_reports/RR2147.html. Accessed 11 Feb 2020.

2. Davis T, Holcombe R, Berkel H, et al. Informed consent for clinical trials: A comparative study of standard versus simplified forms. J Natl Cancer Inst. 1998. doi:10.1093/jnci/90.9.668.

3. Dunn L, Jeste D. Enhancing informed consent for research and treatment. Neuropsychopharmacology. 2001. doi:10.1016/S0893-133X(00)00218-9.

4. Kadam R. Informed consent process: A step further towards making it meaningful! Perspect Clin Res. 2017;8(3):107–12.

5. Hughson J, Woodward-Kron R, Parker A, et al. A review of approaches to improve participation of culturally and linguistically diverse populations in clinical trials.2016:Trials; doi:10.1186/s13063-016-1384-3.

6. McDougall G, Simpson G, Friend M. Strategies for research recruitment and retention of older adults of racial and ethnic minorities. J Geront Nurs. 2015. doi:10.3928/00989134-20150325-01.

7. Redwood S, Gill P. Under-representation of minority ethnic groups in research- call for action. Br J Gen Pract. 2013. doi:10.3399/bjgp13X668456.

8. Witham MD, Anderson E, Carroll C, et al. Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process. Trials. 2020. doi.org/10.1186/s13063-020-04613-7.

9. Wang V. Encyclopedia of Strategic Leadership and Management Hershey, Pennsylvania: IGI Global; 2017. https://igi-global.com. Accessed 19 May 2020.

10. World Health Organisation. Increasing access to health workers in underserved areas: a conceptual framework for measuring results. Bulletin of the World Health Organisation. 2010. Accessed Jun 2020.

11. World Health Organisation. Resolution on Community Health Workers to be considered at the upcoming World Health Assembly. News and Events 29 January 2019 https://www.who.int/hrh/news/2019/community-health-workers-resolution-at-wha/en/. Accessed Jun 2020.
12. Papoutsi C, Mattick K, Pearson M, Brennan N, Briscoe S, Wong G. Social and professional influences on antimicrobial prescribing for doctors-in-training: a realist review. J Antimicrobial Chemo. 2017. doi:10.1093/jac/dkx194.

13. Flory J, Emmanuel E. Interventions to improve research participants’ understanding in informed consent for research: a systematic review. JAMA. 2004. doi:10.1001/jama.292.13.1593.

14. Montalvo W, Larson E. Participant comprehension of research for which they volunteer: a systematic review. J Nurs Schol. 2014. doi:10.1111/jnu.12097.

15. Pandiya A. Readability and comprehensability of informed consent forms for clinical trials. Perspect Clin Res. 2010;1:98–100.

16. HRA. Applying a proportionate approach to the process of seeking consent. 2017. http://www.file:///C:/Users/mhsman/Downloads/Proportionate_approach_to_seeking_consent_HRA_Guidance.pdf. Accessed: 20 Apr 2020.

17. Joffe S, Cook E, Cleary P, et al. Quality of informed consent in cancer clinical trials: A cross-sectional survey. Lancet. 2001. doi:10.1016/S0140-6736(01)06805-2.

18. Nishimura A, Carey J, Erwin P. Improving understanding in the research informed consent process: a systematic review of 54 interventions tested in randomised control trials. BMC Medical Ethics. 2013. doi:10.1186/1472-6939-14-28.

19. Pandya-Wood R, Barron D, Elliot J. A framework for public involvement at the design stage of NHS health and social care research: time to develop ethically conscious standards. Research Involvement Engagement. 2017. doi:10.1186/s40900-017-0058-y.

20. Thanh Tam N, Tien Huy N, Bich Thoa L, et al. Participants’ understanding of informed consent in clinical trials over three decades: systematic review and meta-analysis. Bulletin of the World Health Organisation.2015:93:186–98.

21. Jimison H, Sher P, Appleyard R, et al. The Use of Multimedia in the Informed Consent Process. J Amer Med Info Assoc. 1998. doi:10.1136/jamia.1998.0050245.

22. Department of Health and Social Care. Policy paper. The future of healthcare: our vision for digital, data and technology in health and care 2018. Accessed 19 May 2020.

23. World Health Organisation. Draft Global Strategy on Digital Health. 2020. http://www.who.int/docs/default-source/documents/gs4dhdaa2a9f352b0445bafbc79ca799dce4d.pdf?sfvrsn=f112ede5_38. Accessed 16 May 2020.

24. Manrai A, Birgit H, Funke P, et al. Genetic Misdiagnoses and the Potential for Health Disparities. N Eng. J Med. 2016. doi:10.1056/NEJMsa1507092.

25. Popejoy A, Fullerton S. Genomics is failing on diversity. Nature. 2016. doi:10.1038/538161a.

26. Kirby T. Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities. The Lancet Respiratory Medicine. 2020. doi:10.1016/S2213-2600(20)30228-9.

27. O’Neill O. Some limits of informed consent. J Med Ethics. 2003. doi:10.1136/jme.29.1.4.

28. Pawson R, Greenhalgh T, Harvey G, et al. Realist Synthesis: An Introduction 2004. http://www.ccsr.ac.uk/methods/. Accessed 10 Feb 2020.

29. Wong G. Data Gathering in realist reviews. Looking for needles in haystacks. In: Emmel, N, Greenhalgh, J, Manzano et al. Doing Realist Research London Sage. 2018. p. 132.

30. Pearson M. Realist synthesis: What is it and why might I want to use it? 2011. http://www.medicine.exeter.ac.uk/media/universityofexeter/medicalschool/research/pentag/20111-12-06_Pearson_Realist_review_What_How_Why.pdf. Accessed 15 Feb 2020.
31. Pawson R, Greenhalgh T, Harvey G, Walshe K. Realist Review - a new method of systematic review designed for complex policy interventions. J Health Serv Res Policy. 2005. doi:10.1258/1355819054308530.

32. Pawson R. Evidence-based Policy: A Realist Perspective. Can J Prog Eval. 2006;23(2):268–70.

33. Moher D. et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews. 2015;4:1.

34. NCCfP. Online Engagement: A guide to creating and running virtual meetings and events 2020. http://www.publicengagement.ac.uk/sites/default/files/publication/creating_and_running_virtual_events_-_april_2020_v1.pdf. Accessed 13 Apr 2020.

35. Leigh-Hunt D. Identifying and managing internal and external stakeholder interests. Understanding Organisations: Identifying and managing internal and external stakeholder interests. Health Knowledge Education, CPD and Revalidation from Phast 2016. http://www.healthknowledge.org.uk/public-health-textbook/organisation-management/5b-understanding-ofts/managing-internal-external-stakeholders. Accessed 19 May 2020.

36. Carrieri D, Pearson M, Mattick K, et al. Interventions to minimise doctors’ mental ill-health and its impacts on the workforce and patient care: the Care Under Pressure realist review. Health Serv Deliv Res. 2020. doi:10.3310/hsdr08190.

37. INVOLVE Patient and public involvement in research and research ethics committee review. 2009. http://www.invo.org.uk/wp-content/uploads/2011/12/INVOLVENRESfinalStatement310309.pdf. Accessed 12 Jun 2020.

38. Wong G, Greenhalgh T, Westhorp G, et al. Development of methodological guidance, publication standards and training materials for realist and meta-narrative reviews: the RAMESES (Realist and Meta-narrative Evidence Syntheses - Evolving Standards) project. Health Serv Deliv Res. 2014a. doi:10.3310/hsdr02300.

39. National Institute for Health Research. Research Champions 2020. http://www.nihr.ac.uk/patients-carers-and-the-public/i-want-to-help-with-research/research-champions.htm. Accessed 20 Apr 2020.

40. Hurwitz B, Greenhalgh T, Skultans V. Narrative Research in Health and Illness. Oxford: Blackwell Publishing Ltd; 2004. doi:10.1002/9780470755167.

41. Emmel N, Greenhalgh J, Manzano A, et al. Doing Realist Research. London: Sage; 2018. doi:10.4135/9781526451729.

42. Mogre V, Scherbrier A, Dorman T. A realist review of educational interventions to improve the delivery of nutrition care by doctors and future doctors. Syst Reviews. 2014. doi:10.1186/2046-4053-3-148.

43. Rivas C, Vigours C, Cameron J, et al. A realist review of which advocacy interventions work for which abused women under what circumstances. Cochrane Database of Systematic Reviews. 2019. doi:10.1002/14651858.CD013135.

44. Rycroft-Malone J, McCormack B, Hutchinson A. Realist synthesis: illustrating the method for implementation research. Impl Science. 2012. doi:10.1186/1748-5908-7-33.

45. Weetman K, Wong H, Scott E, et al. Improving best practice for patients receiving hospital discharge letters: a realist review protocol. BMJ Open. 2017. doi:10.1136/bmjopen-2017-018353.

46. Ahikari B, Vincent R, Wong G. A realist review of community engagement with health research. Wellcome Open Research 2019; 4(87).

47. Gough D. Weight of evidence: a framework for the appraisal of the quality and relevance of evidence. Research Papers in Education.2007;22(2):213–28.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

- AdditionalFile1DraftMEDLINEsearchstrategy.doc
- PRISMAPChecklist.docx